Login / Signup

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma.

Lazaros LazaridisElisabeth BumesDorothee Cäcilia SpilleTim SchulzSina HeiderSarina AgkatsevTeresa SchmidtTobias BlauChristoph OsterJonas FeldheimWalter StummerAlmuth Friederike KesslerClemens SeidelOliver GrauerPeter HauUlrich SureKathy KeyvaniUlrich HerrlingerChristoph KleinschnitzMartin StuschkeKen HerrmannCornelius DeuschlStella BreuerElke HattingenBjörn SchefflerSied KebirMartin Glas
Published in: Neuro-oncology advances (2022)
The results from this multicentric trial indicate that-under real-life conditions-toxicity and survival estimates are comparable to the CeTeG/NOA-09 trial. TTFields therapy for at least eight weeks in combination with this regimen was independently associated with prolonged survival.
Keyphrases
  • newly diagnosed
  • phase iii
  • study protocol
  • phase ii
  • clinical trial
  • dna methylation
  • free survival
  • transcription factor
  • randomized controlled trial
  • open label
  • low grade